Latest Eisai Co Ltd Spons A (ESALY) Headlines
Post# of 16
Posted On: 03/09/2014 6:44:16 PM
Latest Eisai Co Ltd Spons A (ESALY) Headlines
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in
George Budwell, The Motley Fool - Motley Fool - Fri Feb 14, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Can These Obesity Drug Stocks Bounce Back in 2014?
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 1:34PM CST
Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as...
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Are Smoking Cessation Drugs Better Than Nicotine-based Products?
Leo Sun, The Motley Fool - Motley Fool - Mon Jan 27, 12:45PM CST
Follow @leokornsun // full story)
JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc.
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 16, 11:20AM CST
On Monday we kicked off the start of the 2014 JPMorgan Healthcare Conference, which is arguably the most important health care conference of the year, bringing together pharmaceutical, biotechnology, and medical device makers all under one roof. ...
10 Countries With the Longest Life Expectancy
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 10, 12:35PM CST
Having been a health care junkie for the better part of a decade now, I still stop and marvel at how impressively global life expectancy rates have improved over the past couple of decades, especially considering that the World Health Organization...
Pipeline Progress at Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 3:05PM CST
Corcept recently announced plans to extend its development program for glucocorticoid receptor (GR) antagonists, including Korlym, into oncology.
The Good News, Bad News for Belviq: …Now the Good News
Eric Ho, The Motley Fool - Motley Fool - Tue Nov 26, 9:57AM CST
Belviq, Arena Pharmaceuticals ' (NASDAQ: ARNA) lead obesity drug, continues to rack up mediocre sales numbers as sales performance continues to lag expectations. Fans of Belviq and Arena still see the drug as a potential blockbuster but questions...
The Good News, Bad News for Belviq: Bad News First…
Eric Ho, The Motley Fool - Motley Fool - Thu Nov 21, 2:02PM CST
Arena Pharmaceuticals and its lead product, weight loss drug Belviq, have had a difficult run since Belviq's launch in June. On its recent conference call, Arena's marketing partner Eisai reported anemic third-quarter Belviq sales of only $4.8...
Arena adds to gains on new Belviq marketing deal
AP - Mon Nov 11, 11:46AM CST
NEW YORK (AP) — Shares of Arena Pharmaceuticals continued to rise Monday after the company expanded a marketing partnership on its weight-loss drub Belviq.
Arena Pharma Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 08, 3:00PM CST
Arena Pharmaceuticals reported net loss per share of 10 cents in the third quarter of 2013.
Arena rises after expanding drug marketing deal
AP - Fri Nov 08, 12:52PM CST
NEW YORK (AP) — Shares of Arena Pharmaceuticals climbed Friday after the company said it expanded its marketing arrangement with Eisai Co., its partner on the weight-loss drug Belviq.
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in
George Budwell, The Motley Fool - Motley Fool - Fri Feb 14, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Can These Obesity Drug Stocks Bounce Back in 2014?
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 1:34PM CST
Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as...
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Are Smoking Cessation Drugs Better Than Nicotine-based Products?
Leo Sun, The Motley Fool - Motley Fool - Mon Jan 27, 12:45PM CST
Follow @leokornsun // full story)
JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc.
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 16, 11:20AM CST
On Monday we kicked off the start of the 2014 JPMorgan Healthcare Conference, which is arguably the most important health care conference of the year, bringing together pharmaceutical, biotechnology, and medical device makers all under one roof. ...
10 Countries With the Longest Life Expectancy
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 10, 12:35PM CST
Having been a health care junkie for the better part of a decade now, I still stop and marvel at how impressively global life expectancy rates have improved over the past couple of decades, especially considering that the World Health Organization...
Pipeline Progress at Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 3:05PM CST
Corcept recently announced plans to extend its development program for glucocorticoid receptor (GR) antagonists, including Korlym, into oncology.
The Good News, Bad News for Belviq: …Now the Good News
Eric Ho, The Motley Fool - Motley Fool - Tue Nov 26, 9:57AM CST
Belviq, Arena Pharmaceuticals ' (NASDAQ: ARNA) lead obesity drug, continues to rack up mediocre sales numbers as sales performance continues to lag expectations. Fans of Belviq and Arena still see the drug as a potential blockbuster but questions...
The Good News, Bad News for Belviq: Bad News First…
Eric Ho, The Motley Fool - Motley Fool - Thu Nov 21, 2:02PM CST
Arena Pharmaceuticals and its lead product, weight loss drug Belviq, have had a difficult run since Belviq's launch in June. On its recent conference call, Arena's marketing partner Eisai reported anemic third-quarter Belviq sales of only $4.8...
Arena adds to gains on new Belviq marketing deal
AP - Mon Nov 11, 11:46AM CST
NEW YORK (AP) — Shares of Arena Pharmaceuticals continued to rise Monday after the company expanded a marketing partnership on its weight-loss drub Belviq.
Arena Pharma Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 08, 3:00PM CST
Arena Pharmaceuticals reported net loss per share of 10 cents in the third quarter of 2013.
Arena rises after expanding drug marketing deal
AP - Fri Nov 08, 12:52PM CST
NEW YORK (AP) — Shares of Arena Pharmaceuticals climbed Friday after the company said it expanded its marketing arrangement with Eisai Co., its partner on the weight-loss drug Belviq.
(0)
(0)